Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models

Sandra Juul

doi:10.1016/j.clp.2004.03.004

Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models

Clin Perinatol. 2004 Mar;31(1):129-42. doi: 10.1016/j.clp.2004.03.004.

Author

Sandra Juul¹

Affiliation

¹ Division of Neonatology, Department of Pediatrics, University of Washington, PO Box 356320, Seattle, WA 98195, USA. sjuul@u.washington.edu

PMID: 15183662
DOI: 10.1016/j.clp.2004.03.004

Abstract

The biologic effects of erythropoietin in the central and peripheral nervous system involve the activation of its specific cell surface receptor and corresponding signal transduction pathways. This article reviews the neuroprotective effects of erythropoietin in brain, emphasizing the progress made using in vitro and in vivo research models.

Publication types

Research Support, U.S. Gov't, P.H.S.
Review

MeSH terms

Animals
Animals, Newborn
Brain / drug effects*
Brain / metabolism
Erythropoietin / pharmacology*
Erythropoietin / therapeutic use
Ganglia, Spinal / drug effects
Humans
In Vitro Techniques
Infant, Newborn
Neonatology / methods
Neuroprotective Agents / pharmacology*
Neuroprotective Agents / therapeutic use
Receptors, Erythropoietin / metabolism
Recombinant Proteins
Retina / drug effects

Substances

Neuroprotective Agents
Receptors, Erythropoietin
Recombinant Proteins
Erythropoietin

Grants and funding

HD042213-01/HD/NICHD NIH HHS/United States